At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pembrolizumab and Radiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Not Eligible for Cisplatin Therapy
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Intensity Modulated Radiation Therapy for Head and Neck Cancer. Completed, enrolled 29 participants across 3 sites.
Detailed Summary
This study is being done to evaluate the efficacy of Pembrolizumab, concomitant with and following standard of care definitive radiation, for locally advanced squamous cell carcinoma of the head and neck patients who are not good candidates for Cisplatin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartMay 2016
Primary CompletionDec 2019
Study CompletionNov 2023
TodayJul 2026
First PostedNov 20, 2015
Enrollment StartMay 16, 2016
Primary CompletionDec 23, 2019
Study CompletionNov 20, 2023
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 10.6 years ago
Interventions
Pembrolizumabdrug
Pembrolizumab, 200 mg IV during cycle visits every 3-weeks for up to 6 cycles, or until toxicities are no longer tolerable
Intensity Modulated Radiation Therapyradiation
Eligible participants will receive Intensity Modulated Radiation Therapy daily x 7 weeks